Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases

A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop a progressive phenotype characterised by decline in lung function, worsening quality of life and early mortality. Other than idiopathic pulmonary fibrosis (IPF), there are no approved drugs for fibrosing ILDs and a poo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Respir J
Main Authors: Wollin, Lutz, Distler, Jörg H.W., Redente, Elizabeth F., Riches, David W.H., Stowasser, Susanne, Schlenker-Herceg, Rozsa, Maher, Toby M., Kolb, Martin
Formato: Artigo
Idioma:Inglês
Publicado em: European Respiratory Society 2019
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6751387/
https://ncbi.nlm.nih.gov/pubmed/31285305
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/13993003.00161-2019
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados